Navigation Links
Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019
Date:5/15/2012

313.6 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -the UK 323.7 Neuroendocrine Carcinoma Therapeutics Market Size (2005-2010)- France 333.8 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) - France 343.9 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) - Germany 353.10 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -Germany 363.11 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) - Italy 373.12 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -Italy 383.13 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) - Spain 393.14 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) - Spain 403.15 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) – Japan 413.16 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) - Japan 423.17 Drivers and Barriers for Neuroendocrine Carcinoma Therapeutics Market 433.17.1 Drivers for the Neuroendocrine Carcinoma Therapeutics Market 433.17.2 Barriers for the Neuroendocrine Carcinoma Therapeutics Market 433.18 Key Events Impacting the Future Market 443.19 Opportunity and Unmet Need 443.19.1 Gastrointestinal carcinoid (NETs) 453.19.2 Pancreatic NETs 453.20 Key Takeaway 464 Neuroendocrine Carcinoma Therapeutics Market- Competitive Assessment 474.1 Overview 474.1.1 Strategic Competitor Assessment 474.2 Product Profiles for the Major Marketed Products in Neuroendocrine Carcinoma 494.2.1 Afinitor (everolimus, RAD001) 494.2.2 Sutent (sunitinib) 504.2.3 Sandostatin LAR (octreotide acetate) 514.3 Key Takeaway 515 Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment 525.1 Overview 525.2 Strategic Pipeline Assessment 525.3 Analysis by Phase of Development 535.3.1 Neuroendocrine Carcinoma Therapeutics - Phase III Pipeline 535.3.2 Neuroendocrine Carcinoma Therapeutics - Phase II Pipeline 545.3.3 Neuroendocrine Carcinoma Therapeutics- Phase I Pipeline 545.3.4 Neuroendocrine Carcinoma Therapeutics -
'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
2. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
3. Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood
4. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
5. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
6. Targeted Gold Nanoparticles and Noninvasive Radio Fields Attacking One of the Deadliest and Least Curable Types of Cancer: Pancreatic Carcinoma
7. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
8. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
9. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
10. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
11. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... 2015 results before the Nasdaq market opens on Thursday, ... call and webcast to discuss its financial results and ... at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time). ... by dialing 866-952-1906 (US) or 785-424-1825 (International) using the ...
(Date:4/23/2015)... Calif. , April 23, 2015  Veracyte, Inc. (NASDAQ: ... into a definitive agreement to sell approximately $40 million ... the agreement, the investors will purchase an aggregate of ... of $8.15 per share, the closing stock price on ... new and existing investors, including Broadfin Capital, Camber Capital, ...
(Date:4/23/2015)... -- Metanome, Inc., an industry leader in comprehensive microbiome ... name to Diversigen, Inc.  The name was changed ... source for the myriad of services and expertise ... of the microbiome.  From the wide diversity in ... that are difficult to handle, such as low ...
(Date:4/23/2015)... 2015 Delpor, Inc. (Delpor), a biotechnology ... United States Patent and Trademark Office has issued 2 ... technology. US Pat. No. 8,986,727 was issued on ... delivery device for the sustained release of therapeutic ... the sustained (zero-order) release of large and small molecules ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Metanome Announces Corporate Name Change to Diversigen 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3
... 27 MichBio, the association for,Michigan,s biosciences industry, ... to its program on day one of its ... Rock Financial ShowPlace Novi, MI. The,event will provide ... bioscience technologies and emerging companies to an audience ...
... FRANCISCO, Aug. 27 Nile Therapeutics,Inc., (Nasdaq: NLTX ... Nile, will present at the NewsMakers in the Biotech ... at the Millennium,Broadway Hotel in New York City. Mr. ... status of Nile,s current clinical development,programs., The presentation ...
... of students with known allergies are urged to put auto-injectable ... epinephrine at the top of the school supplies list, ... by,the National Association of School Nurses (NASN) found that 72% ... or prior use of,epinephrine whose parents have not provided the ...
Cached Biology Technology:Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo 2Nile Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference 2Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School 2Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School 3Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School 4
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition ... Report" report to their offering. This report analyzes ... by the following Segments: Face Biometrics, and Voice Biometrics. The report ... , Japan , Europe , ... & Africa , and Latin America ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ... solutions, today announced that its U.are.U ® ... retailer Goorin Bros . to achieve PCI ... solution secures access to the POS terminal, protecting ... risk of data breaches. With ...
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... CITY A team of researchers, led by physicians ... ARUP Laboratories, has made a medical breakthrough by discovering ... disease. The disease, pulmonary capillary hemangiomatosis or PCH, ... predominantly in young adults. PCH affects less than one ...
... CORAL GABLES, FL (February 4, 2014) ... builds on existing scholarship exploring the role of robotics ... their widespread deployment everywhere from the home, to hospitals, ... existing legal regimes or requires rethinking of various policy ...
... Cancer Center have discovered a new signaling pathway ... of diseases such as cancer, multiple sclerosis and ... role that activation of interferon-regulatory factor 1 (IRF1), ... of a variety of target genes, plays in ...
Cached Biology News:New hope: Researchers discover genetic mutations that cause rare and deadly lung disease 2New hope: Researchers discover genetic mutations that cause rare and deadly lung disease 3We Robot 2014 April 4th & 5th at University of Miami School of Law 2Newly discovered signaling pathway could impact a variety of autoinflammatory diseases 2
... Anti-AP-2 α, clone 8G8/5 GenBank ... Bacterially made human AP-2alpha/gamma fusion protein corresponding ... residues 278-450 of human AP-2γ Formulation: 0.1M ... azide before the addition of glycerol to ...
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
MMP-2 / MMP-9 Inhibitor IV is a potent, selective, slow binding and mechanism based inhibitor of human gelatinases. • Molecular weight: 306.4 • Molecular Formula: C(15)H(14)O(3)S(2). &bul...
... (MUC3) is a glycoprotein. distributed in ... extent in breast, lung and salivary gland ... cross-reaction with MUC1 and MUC2. ... Immunogen: MUC3 tandem repeat peptide ...
Biology Products: